1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

huge restructure (i.e. firings on the way)

Discussion in 'Genoptix' started by Anonymous, Jul 16, 2015 at 3:03 PM.

  1. Anonymous

    Anonymous Guest

    Came back from a meeting where i heard that the senior upper management will cull the salesforce and management team. Employee cuts are in order across the board.

    Rumors,.... if under performing, then PIP with expectation that you will not be able to hit your PIP and termination will follow without paying unemployment or severance.

    Beware to all who are under 80%.
     
  2. Anonymous

    Anonymous Guest

    70% flow cuts coming in 2016. Most hematology labs are going to close in 2016.
     
  3. anonymous

    anonymous Guest

    you put all your eggs in the flow basket. and someone put a steaming hot dump in that basket.
     
  4. anonymous

    anonymous Guest

    I just read an article from aacc.org about president Obama signing a bill that basically cuts Medicare reimbursement up to 75%. The good news is that the actual cuts won't start until 2017 and are only scheduled to be 10-15% per year until 2022. They are using data collected from 2016 to justify the appropriate payment. This means we have time to brace and realign our employees. We can make 10% improvements we just need to keep an open mind and hope that management reacts with a sense of urgency but stays calm and collected. I believe in us!
     
  5. anonymous

    anonymous Guest

    The flow cuts are not gradual. They are in the 2016 CMS proposed fee schedule. Maybe you should bring back that winner AQUA?
     
  6. anonymous

    anonymous Guest

    I dont wish anyone to lose their job but as a lab sales professional for many years I am interested to see what happens. When you cant operate on a said margin- sh*+ gets real.
     
  7. anonymous

    anonymous Guest

    Novartis doesn't need Genoptix to be profitable. The sole reason the company was purchased was for data. It has been known Genoptix will raise sales expectations to beyond what the market has to offer until reps stop making commission and eventually quit. They will be a skeleton crew of sales reps over the next 3 years. They are continuing to lose ground to other labs and bring nothing new to the market. How can anyone really believe that is sustainable let alone successful. I'm already on the hunt for a new job, not going to wait me to run out of my job via PIP.
     
  8. anonymous

    anonymous Guest


    Bluckety bluckety blah blah blah. It sucks you suk we all suck. Kiss my fat blonde ass and you can fluckety flah flah flah